A new approach to drug formulation may enable the self-administration of drugs that last up to 2 years.

Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full-year ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported ...

First-in-human studies anticipated to begin in 2026Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of ...

General transcription factor IIIC subunit 2 (GTF3C2) is one of the polymerase III transcription-related factors. Previous studies have revealed that ...

Tharimmune (THAR) announced preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized ...

BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a ...

The oral administration of exenatide was compared with the subcutaneous injection (s.c.) of 10 µg/kg exenatide ... and in vivo in normoglycaemic mice, the ability of exenatide-loaded lipid ...

Experiments using mouse subcutaneous tumor models confirmed that the combination ... The first group received intratumor injections of PBS three times a week, serving as a placebo. The second group ...

Based on the findings, the scientists developed a treatment strategy to block specific inflammatory molecules, which eased MS severity in the mouse ... subcutaneous, or under-the-skin, injection ...

Lundbeck has stopped development of a subcutaneous formulation of its migraine drug Lu AG09222 as the Danish drugmaker ...